Personalized Needs in Clostridium Difficile Infections (SPECIFY)
Scoring Personalized Needs in Clostridium Difficile Infections for Fidaxomixin Therapy
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Medical world is nowadays witnessing a sudden increase of the incidence of infections by Clostridium difficile (DCI). This is due in part to the prolongation of survival of patients with major comorbidities like solid tumor malignancies and lymphomas but also to the widespread intake of proton pump inhibitors and of wide-spectrum antimicrobials. It is highly probable that isolates of C.define causing this pandemic are genetically different than isolates of the same species predominating 20 years ago. This hypothesis is developed based on data of the epidemiology of CDI: in old times administration of clindamycin and ampicillin were the main drivers of CDI; recent studies report fluoroquinolones, 2nd and 3rd generation cephalosporins and even vancomycin (i.e. a drug of choice for CDI) to be linked with the development of CDI.
One major hurdle in management of CDI is relapse; the risk of relapse is reported as 15-20% after the first episode; however it is geometrically increased to even 60-80% after the second episode. As a consequence, management of CDI becomes a major health problem.
Fidaxomicin is a novel compound active against species of C.dificille. Results of two recent double-blind, randomized, large scale clinical studies have shown that oral treatment for 10 days with fidaxomicin 200mg bid was non-inferior to oral treatment with vancomycin 125mg q6h. However, the risk of relapse after treatment with vancomycin was close to 25% and with fidaxomicin close to 15%. This difference was statistically significant in both trials outscoring the superiority of fidaxomicin over vancomycin for the management of CDI. Moreover, meta-analysis has shown a significant reduction in mortality by fidaxomicin.
Despite proven superiority, prescription of fidaxomicin is limited to few cases mostly due to high cost. In many countries prescription is restricted to cases of relapsing CDI. Clinical feeling coming both from post-marketing experience as well as from published evidence supports the use of fidaxomicin for cases with risk of death and overt risk of relapse. However, molecular analysis of the C.difficile pathogen cannot be used as a tool for the prediction of relapse since in relapse cases pathogens carry less than 2 single nucleotide variants of the initial isolate. SPECIFY is aiming to develop a score using both clinical and genetic and biomarker data that can efficiently discriminate patients at risk of severe CDI and at risk of relapse of CDI. This score can become in future a tool to discriminate patients at need for treatment with fidaxomicin instead of traditional treatment with metronidazole/vancomycin.
Tipo de estudio
Inscripción (Actual)
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Athens, Grecia, 10676
- 5th Department of Internal Medicine, Evangelismos Athens General Hospital
-
Athens, Grecia, 11527
- 1st Department of Internal Medicine, "G.Gennimatas" General hospital
-
Athens, Grecia, 11527
- 1st Department of Internal Medicine, Laikon General Hospital
-
Athens, Grecia, 11527
- 3rd Department of Internal Medicine, Sotiria General Hospital
-
Athens, Grecia, 12462
- 4th Department of Internal Medicine, Attikon University Hospital
-
Athens, Grecia, 15126
- 2nd Department of Internal Medicine, Sismanogleion General Hospital
-
Magoula, Grecia, 10918
- 1st Department of Internal Medicine, Thriassio General Hospital
-
Magoula, Grecia, 10918
- 2nd Department of Internal Medicine, Thriasio General Hospital
-
Maroúsi, Grecia, 15123
- 2nd Department of Oncology, Mitera Hospital
-
Piraeus, Grecia
- Infections Unit Tzaneion General Hospital
-
Pátra, Grecia, 36504
- Department of Internal Medicine, Patras University Hospital
-
Thessaloniki, Grecia, 54248
- 1st Department of Internal Medicine, AHEPA University Hospital
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Descripción
Inclusion Criteria:
- Age equal to or more than 18 years
- Both genders
- Diarrhea defined as at least 3 episodes of unformed stools in the last 24 hours according to the Bristol stool chart
- Presence of C.difficile in stool. This is defined as any stool sample positive for the presence of glutamate dehydrogenase (GDH) and for the presence of toxin A and/or B.
Exclusion Criteria:
1. No exclusion criteria exist
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: Solo caso
- Perspectivas temporales: Futuro
Cohortes e Intervenciones
Grupo / Cohorte |
Intervención / Tratamiento |
|---|---|
|
Clostridium difficile infection
Patients with Clostridium difficile-associated diarrhea for development of biomarkers
|
Blood sampling
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Definition of prognostic biomarker
Periodo de tiempo: 12 months
|
Patients with positive score and unfavorable outcome.
Unfavorable outcome is defined as at least one of the following: a) number of patients with severe infection at disease onset; b) number of patients who progress into severe infection; c) number of patients with disease recurrence; and d) number of patients who die
|
12 months
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Athanasios Skoutelis, MD, Evangelismos Athens General Hospital
- Silla de estudio: Evangelos J Giamarellos-Bourboulis, MD, PhD, Attikon Hospital
- Investigador principal: George Chrysos, MD, PhD, Tzaneion Piraeus General Hospital
- Investigador principal: Styliani Symbardi, MD, PhD, Thriassio Elefsis General Hospital
- Investigador principal: Zoi Alexiou, MD, PhD, Thriassio Elefsis General Hospital
- Investigador principal: Kostantinos Syrigos, MD, PhD, Sotiria General Hospital
- Investigador principal: George Daikos, MD, PhD, Laikon Athens General Hospital
- Investigador principal: Panagiotis Gargalianos, MD, PhD, G.Gennimatas Athens General Hospital
- Investigador principal: Malvina Lada, MD, PhD, Sismanogleion General Hospital
- Investigador principal: Charalambos Gogos, MD, PhD, University Hospital of Patras
- Investigador principal: Ilias Athanasiadis, MD, PhD, Mitera General Hospital
- Investigador principal: Symeon Metallidis, MD, PhD, AHEPA Thessaloniki University Hospital
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- CL01
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .